Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

The novel pro-autophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous Non-Small Cell Lung Cancer.

López-Plana A, Fernández-Nogueira P, Muñoz-Guardiola P, Solé-Sánchez S, Megías-Roda E, Pérez-Montoyo H, Jauregui P, Yeste-Velasco M, Gómez-Ferreria M, Erazo T, Ametller E, Recalde-Percaz L, Moragas-Garcia N, Noguera-Castells A, Mancino M, Morán T, Nadal E, Alfón J, Domènech C, Gascon P, Lizcano JM, Fuster G, Bragado P.

Int J Cancer. 2020 Jan 14. doi: 10.1002/ijc.32865. [Epub ahead of print]

PMID:
31943158
2.

Mutations in the Antioxidant KEAP1/NRF2 Pathway Define an Aggressive Subset of NSCLC Resistant to Conventional Treatments.

Nadal E, Palmero R, Muñoz-Pinedo C.

J Thorac Oncol. 2019 Nov;14(11):1881-1883. doi: 10.1016/j.jtho.2019.08.005. No abstract available.

PMID:
31668314
3.

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators.

Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4.

PMID:
31591063
4.

Comment on an external validation of the 8th edition of the TNM classification for lung cancer staging in patients treated with chemoradiation.

Palmero R, Navarro-Martin A, Nadal E.

Ann Transl Med. 2019 Jul;7(Suppl 3):S101. doi: 10.21037/atm.2019.04.81. No abstract available.

5.

Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.

Evrard SM, Taranchon-Clermont E, Rouquette I, Murray S, Dintner S, Nam-Apostolopoulos YC, Bellosillo B, Varela-Rodriguez M, Nadal E, Wiedorn KH, Melchior L, Andrew E, Jones M, Ridgway J, Frykman C, Lind L, Rot M, Kern I, Speel EJM, Roemen GMJM, Trincheri N, Freiberger SN, Rechsteiner M.

J Mol Diagn. 2019 Nov;21(6):1010-1024. doi: 10.1016/j.jmoldx.2019.06.010. Epub 2019 Aug 22.

6.

Exploiting metabolic vulnerabilities of Non small cell lung carcinoma.

Majem B, Nadal E, Muñoz-Pinedo C.

Semin Cell Dev Biol. 2019 Jul 2. pii: S1084-9521(18)30186-1. doi: 10.1016/j.semcdb.2019.06.004. [Epub ahead of print] Review.

7.

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.

Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguet AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, De Ruysscher D.

Lung Cancer. 2019 Jul;133:83-87. doi: 10.1016/j.lungcan.2019.05.001. Epub 2019 May 3.

PMID:
31200833
8.

Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases.

Ponce S, Bruna J, Juan O, López R, Navarro A, Ortega AL, Puente J, Verger E, Bartolomé A, Nadal E.

Crit Rev Oncol Hematol. 2019 Jun;138:190-206. doi: 10.1016/j.critrevonc.2019.03.017. Epub 2019 Apr 3. Review.

PMID:
31092376
9.

Functional Network Analysis Reveals the Relevance of SKIIP in the Regulation of Alternative Splicing by p38 SAPK.

Carbonell C, Ulsamer A, Vivori C, Papasaikas P, Böttcher R, Joaquin M, Miñana B, Tejedor JR, de Nadal E, Valcárcel J, Posas F.

Cell Rep. 2019 Apr 16;27(3):847-859.e6. doi: 10.1016/j.celrep.2019.03.060.

10.

Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes.

Peiró I, Palmero R, Iglesias P, Díez JJ, Simó-Servat A, Marín JA, Jiménez L, Domingo-Domenech E, Mancho-Fora N, Nadal E, Villabona C.

Endocrine. 2019 Jun;64(3):605-613. doi: 10.1007/s12020-019-01871-7. Epub 2019 Feb 25.

PMID:
30805887
11.

Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.

Bergamino M, Rullan AJ, Saigí M, Peiró I, Montanya E, Palmero R, Ruffinelli JC, Navarro A, Arnaiz MD, Brao I, Aso S, Padrones S, Cardenal F, Nadal E.

BMC Cancer. 2019 Feb 21;19(1):165. doi: 10.1186/s12885-019-5370-5.

12.

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.

Nadal E, Massuti B, Dómine M, García-Campelo R, Cobo M, Felip E.

Cancer Immunol Immunother. 2019 Mar;68(3):341-352. doi: 10.1007/s00262-019-02310-2. Epub 2019 Feb 6. Review.

PMID:
30725206
13.

Sensitive high-throughput single-cell RNA-seq reveals within-clonal transcript correlations in yeast populations.

Nadal-Ribelles M, Islam S, Wei W, Latorre P, Nguyen M, de Nadal E, Posas F, Steinmetz LM.

Nat Microbiol. 2019 Apr;4(4):683-692. doi: 10.1038/s41564-018-0346-9. Epub 2019 Feb 4.

14.

Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.

Román M, López I, Guruceaga E, Baraibar I, Ecay M, Collantes M, Nadal E, Vallejo A, Cadenas S, Miguel ME, Jang JH, Martin-Uriz PS, Castro-Labrador L, Vilas-Zornoza A, Lara-Astiaso D, Ponz-Sarvise M, Rolfo C, Santos ES, Raez LE, Taverna S, Behrens C, Weder W, Wistuba II, Vicent S, Gil-Bazo I.

Cancer Res. 2019 Feb 1;79(3):625-638. doi: 10.1158/0008-5472.CAN-18-1479. Epub 2018 Dec 18.

PMID:
30563891
15.

Rapid reversible changes in compartments and local chromatin organization revealed by hyperosmotic shock.

Amat R, Böttcher R, Le Dily F, Vidal E, Quilez J, Cuartero Y, Beato M, de Nadal E, Posas F.

Genome Res. 2019 Jan;29(1):18-28. doi: 10.1101/gr.238527.118. Epub 2018 Dec 6.

16.

Endo-therapies for biliary duct-to-duct anastomotic stricture after liver transplantation: Outcomes of a nationwide survey.

Cantù P, Tarantino I, Baldan A, Mutignani M, Tringali A, Lombardi G, Cerofolini A, Di Sario A, Catalano G, Bertani H, Ghinolfi D, Boarino V, Masci E, Bulajic M, Pisani A, Fantin A, Ligresti D, Barresi L, Traina M, Ravelli P, Forti E, Barbaro F, Costamagna G, Rodella L, Maroni L, Salizzoni M, Conigliaro R, Filipponi F, Merighi A, Staiano T, Monteleone M, Mazzaferro V, Zucchi E, Zilli M, Nadal E, Rosa R, Santi G, Parzanese I, De Carlis L, Donato MF, Lampertico P, Maggi U, Caccamo L, Rossi G, Vecchi M, Penagini R.

Liver Int. 2019 Jul;39(7):1355-1362. doi: 10.1111/liv.14010. Epub 2019 May 22.

PMID:
30500104
17.

A novel mechanism for the prevention of transcription replication conflicts.

Canal B, Duch A, Posas F, de Nadal E.

Mol Cell Oncol. 2018 Mar 28;5(3):e1451233. doi: 10.1080/23723556.2018.1451233. eCollection 2018.

18.

Phosphorylation and Proteasome Recognition of the mRNA-Binding Protein Cth2 Facilitates Yeast Adaptation to Iron Deficiency.

Romero AM, Martínez-Pastor M, Du G, Solé C, Carlos M, Vergara SV, Sanvisens N, Wohlschlegel JA, Toczyski DP, Posas F, de Nadal E, Martínez-Pastor MT, Thiele DJ, Puig S.

mBio. 2018 Sep 18;9(5). pii: e01694-18. doi: 10.1128/mBio.01694-18.

19.

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M.

Lancet Respir Med. 2018 Oct;6(10):771-781. doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9.

20.

MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer.

Saigi M, Alburquerque-Bejar JJ, Mc Leer-Florin A, Pereira C, Pros E, Romero OA, Baixeras N, Esteve-Codina A, Nadal E, Brambilla E, Sanchez-Cespedes M.

Clin Cancer Res. 2018 Sep 15;24(18):4579-4587. doi: 10.1158/1078-0432.CCR-18-0267. Epub 2018 Jun 13.

21.

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.

Mainardi S, Mulero-Sánchez A, Prahallad A, Germano G, Bosma A, Krimpenfort P, Lieftink C, Steinberg JD, de Wit N, Gonçalves-Ribeiro S, Nadal E, Bardelli A, Villanueva A, Bernards R.

Nat Med. 2018 Jul;24(7):961-967. doi: 10.1038/s41591-018-0023-9. Epub 2018 May 28.

PMID:
29808006
22.

Genetic and cellular sensitivity of Caenorhabditis elegans to the chemotherapeutic agent cisplatin.

García-Rodríguez FJ, Martínez-Fernández C, Brena D, Kukhtar D, Serrat X, Nadal E, Boxem M, Honnen S, Miranda-Vizuete A, Villanueva A, Cerón J.

Dis Model Mech. 2018 Jun 21;11(6). pii: dmm033506. doi: 10.1242/dmm.033506.

23.

Timing of gene expression in a cell-fate decision system.

Aymoz D, Solé C, Pierre JJ, Schmitt M, de Nadal E, Posas F, Pelet S.

Mol Syst Biol. 2018 Apr 25;14(4):e8024. doi: 10.15252/msb.20178024.

24.

Preoperative nutritional status assessment predicts postoperative outcomes in patients with surgically resected non-small cell lung cancer.

Ramos R, Nadal E, Peiró I, Masuet-Aumatell C, Macia I, Rivas F, Rosado G, Rodriguez P, Ureña A, Padrones S, Aso S, Deniz C, Navarro A, Escobar I.

Eur J Surg Oncol. 2018 Sep;44(9):1419-1424. doi: 10.1016/j.ejso.2018.03.026. Epub 2018 Apr 11.

PMID:
29685760
25.

Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease.

Doménech M, Jové M, Aso S, Marín M, Nadal E.

Lung Cancer. 2018 May;119:99-102. doi: 10.1016/j.lungcan.2018.03.014. Epub 2018 Mar 17.

PMID:
29656760
26.

Plug-and-Play Multicellular Circuits with Time-Dependent Dynamic Responses.

Urrios A, Gonzalez-Flo E, Canadell D, de Nadal E, Macia J, Posas F.

ACS Synth Biol. 2018 Apr 20;7(4):1095-1104. doi: 10.1021/acssynbio.7b00463. Epub 2018 Apr 2.

PMID:
29584406
27.

Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer.

Zugazagoitia J, Biosca M, Oliveira J, Olmedo ME, Dómine M, Nadal E, Ruffinelli JC, Muñoz N, Luna AM, Hernández B, Martínez M, Gallego I, Martínez de Castro E, Font C, Calvo V, Martínez-Marín V, Corral J, Noguerón E, Mondéjar R, García Escobar I, Salvador-Coloma C, Juan Ó, Sánchez Cánovas M, Valdivia J, Ochoa MP, López Castro R, Obispo B, Pangua C, Sereno M, Fernández Franco L, Mielgo X, Calzas J, Blasco A, Aparisi F, Chara L, Grau JF, Soares M, Gómez A, Zenzola V, García-Morillo M, Cacho D, Díaz-Serrano A, Aguado C, Ponce-Aix S, González-Larriba JL, Muñoz AJ, Lora D, Paz-Ares L, Manzano A.

Eur Respir J. 2018 May 3;51(5). pii: 1702431. doi: 10.1183/13993003.02431-2017. Print 2018 May. No abstract available.

28.

Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII-p38MAPK-pS249/T252RB Pathway.

Yu-Lee LY, Yu G, Lee YC, Lin SC, Pan J, Pan T, Yu KJ, Liu B, Creighton CJ, Rodriguez-Canales J, Villalobos PA, Wistuba II, de Nadal E, Posas F, Gallick GE, Lin SH.

Cancer Res. 2018 Jun 1;78(11):2911-2924. doi: 10.1158/0008-5472.CAN-17-1051. Epub 2018 Mar 7.

29.

Optical Properties of Complex Plasmonic Materials Studied with Extended Effective Medium Theories Combined with Rigorous Coupled Wave Analysis.

Nadal E, Barros N, Glénat H, Kachakachi H.

Materials (Basel). 2018 Feb 27;11(3). pii: E351. doi: 10.3390/ma11030351.

30.

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.

Román M, Baraibar I, López I, Nadal E, Rolfo C, Vicent S, Gil-Bazo I.

Mol Cancer. 2018 Feb 19;17(1):33. doi: 10.1186/s12943-018-0789-x. Review.

31.

Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer.

Antonio M, Saldaña J, Linares J, Ruffinelli JC, Palmero R, Navarro A, Arnaiz MD, Brao I, Aso S, Padrones S, Navarro V, González-Barboteo J, Borràs JM, Cardenal F, Nadal E.

Br J Cancer. 2018 Mar 6;118(5):639-647. doi: 10.1038/bjc.2017.455. Epub 2018 Jan 30.

32.

Multiple signaling kinases target Mrc1 to prevent genomic instability triggered by transcription-replication conflicts.

Duch A, Canal B, Barroso SI, García-Rubio M, Seisenbacher G, Aguilera A, de Nadal E, Posas F.

Nat Commun. 2018 Jan 25;9(1):379. doi: 10.1038/s41467-017-02756-x.

33.

Activation of the Hog1 MAPK by the Ssk2/Ssk22 MAP3Ks, in the absence of the osmosensors, is not sufficient to trigger osmostress adaptation in Saccharomyces cerevisiae.

Vázquez-Ibarra A, Subirana L, Ongay-Larios L, Kawasaki L, Rojas-Ortega E, Rodríguez-González M, de Nadal E, Posas F, Coria R.

FEBS J. 2018 Mar;285(6):1079-1096. doi: 10.1111/febs.14385. Epub 2018 Jan 30.

34.

Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.

Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K.

Clin Lung Cancer. 2018 May;19(3):213-220.e4. doi: 10.1016/j.cllc.2017.11.003. Epub 2017 Nov 21.

35.

Conductive vancomycin-loaded mesoporous silica polypyrrole-based scaffolds for bone regeneration.

Zanjanizadeh Ezazi N, Shahbazi MA, Shatalin YV, Nadal E, Mäkilä E, Salonen J, Kemell M, Correia A, Hirvonen J, Santos HA.

Int J Pharm. 2018 Jan 30;536(1):241-250. doi: 10.1016/j.ijpharm.2017.11.065. Epub 2017 Nov 28.

PMID:
29195917
36.

Regulation of transcription elongation in response to osmostress.

Silva A, Cavero S, Begley V, Solé C, Böttcher R, Chávez S, Posas F, de Nadal E.

PLoS Genet. 2017 Nov 20;13(11):e1007090. doi: 10.1371/journal.pgen.1007090. eCollection 2017 Nov.

37.

Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.

Saigi M, McLeer-Florin A, Pros E, Nadal E, Brambilla E, Sanchez-Cespedes M.

Clin Transl Oncol. 2018 Jul;20(7):881-888. doi: 10.1007/s12094-017-1799-7. Epub 2017 Nov 14.

PMID:
29139039
38.

The Hog1p kinase regulates Aft1p transcription factor to control iron accumulation.

Martins TS, Pereira C, Canadell D, Vilaça R, Teixeira V, Moradas-Ferreira P, de Nadal E, Posas F, Costa V.

Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Jan;1863(1):61-70. doi: 10.1016/j.bbalip.2017.10.001. Epub 2017 Oct 12.

PMID:
29032057
39.

Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma.

Truini A, Coco S, Nadal E, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Biello F, Barletta G, Merlo DF, Valentino A, Ferro P, Ravetti GL, Stigliani S, Vigani A, Fedeli F, Beer DG, Roncella S, Grossi F.

Oncotarget. 2017 Aug 2;8(40):68627-68640. doi: 10.18632/oncotarget.19800. eCollection 2017 Sep 15.

40.

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).

Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer HG, Vivancos A.

Ann Oncol. 2017 Oct 1;28(10):2451-2457. doi: 10.1093/annonc/mdx396.

41.

A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer.

Gasa L, Sanchez-Botet A, Quandt E, Hernández-Ortega S, Jiménez J, Carrasco-García MA, Simonetti S, Kron SJ, Ribeiro MP, Nadal E, Villanueva A, Clotet J.

Sci Rep. 2017 Aug 31;7(1):10228. doi: 10.1038/s41598-017-10770-8.

42.

Interaction Dynamics Determine Signaling and Output Pathway Responses.

Stojanovski K, Ferrar T, Benisty H, Uschner F, Delgado J, Jimenez J, Solé C, de Nadal E, Klipp E, Posas F, Serrano L, Kiel C.

Cell Rep. 2017 Apr 4;19(1):136-149. doi: 10.1016/j.celrep.2017.03.029.

43.

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.

Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, Navarro A, Condom E, Moran S, Gomez-Lopez G, Graña O, Rubio-Camarillo M, Martinez-Martí A, Yokota J, Carretero J, Galbis JM, Nadal E, Pisano D, Sozzi G, Felip E, Montuenga LM, Roz L, Villanueva A, Sanchez-Cespedes M.

Clin Cancer Res. 2017 Jun 15;23(12):3203-3213. doi: 10.1158/1078-0432.CCR-16-1946. Epub 2017 Mar 16.

44.

Role of the Sln1-phosphorelay pathway in the response to hyperosmotic stress in the yeast Kluyveromyces lactis.

Rodríguez-González M, Kawasaki L, Velázquez-Zavala N, Domínguez-Martín E, Trejo-Medecigo A, Martagón N, Espinoza-Simón E, Vázquez-Ibarra A, Ongay-Larios L, Georgellis D, de Nadal E, Posas F, Coria R.

Mol Microbiol. 2017 Jun;104(5):822-836. doi: 10.1111/mmi.13664. Epub 2017 Mar 28.

45.

An RB insensitive to CDK regulation.

Joaquin M, de Nadal E, Posas F.

Mol Cell Oncol. 2016 Dec 14;4(1):e1268242. doi: 10.1080/23723556.2016.1268242. eCollection 2017.

46.

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.

Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, Prat A.

Clin Chem. 2017 Mar;63(3):751-760. doi: 10.1373/clinchem.2016.265314. Epub 2017 Jan 10.

47.

Management of biliary anastomotic strictures after liver transplantation (BASALT study): A nationwide Italian survey.

Cantù P, Parzanese I, Balassone V, Di Sario A, Soggiu F, Lombardi G, Barbaro F, Pisani A, Baldan A, Cariani G, Boarino V, Fasoli A, Bertani H, Forti E, Bulajic M, Ghinolfi D, Nadal E, Cerofolini A, Barresi L, Catalano G, Stroppa I, Traini S, Mazzaferro V, Cipolletta L, Tringali A, Costamagna G, Ravelli P, Bazzoli F, Merighi A, Parodi MC, Conigliaro R, Mutignani M, Zilli M, Filipponi F, Fantin A, Rodella L, Tarantino I, Traina M, Salizzoni M, Rosa R, Malinverno F, Invernizzi F, Manini MA, Donato MF, Colombo M, Conte D, Rossi G, Penagini R.

Liver Transpl. 2017 Feb;23(2):257-261. doi: 10.1002/lt.24701. No abstract available.

48.

Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer.

Garon EB, Reck M, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Lee P, Dalal R, Liu J, He S, Treat J, Nakagawa K.

Clin Lung Cancer. 2017 Jan;18(1):96-99. doi: 10.1016/j.cllc.2016.05.023. Epub 2016 Jun 8.

PMID:
27894601
49.

KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy.

Ambrogio C, Nadal E, Villanueva A, Gómez-López G, Cash TP, Barbacid M, Santamaría D.

ESMO Open. 2016 Sep 6;1(5):e000076. eCollection 2016. Review.

50.

Evolution of protein phosphorylation across 18 fungal species.

Studer RA, Rodriguez-Mias RA, Haas KM, Hsu JI, Viéitez C, Solé C, Swaney DL, Stanford LB, Liachko I, Böttcher R, Dunham MJ, de Nadal E, Posas F, Beltrao P, Villén J.

Science. 2016 Oct 14;354(6309):229-232.

PMID:
27738172

Supplemental Content

Support Center